QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayashi, Y. Search for Related Content PubMed PubMed Citation Articles by Hayashi, Y.

---

Supplement: 2nd Amino Acid Workshop

Application of the Concepts of Risk Assessment to the Study of Amino Acid Supplements¹

NPO Communication Center for Food and Health Sciences, Tokyo 135-0004, Japan

² To whom correspondence should be addressed. E-mail: esato{at}icaas-org.com.

Risk assessment is defined as the use of available scientific information to characterize potentially adverse effects associated with exposure of humans to an agent under known or expected conditions. Practically, risk assessment is intended to provide the scientifically sound basis for regulatory or nonregulatory action to manage the risks in humans from the agent. Therefore, the final goal of risk assessment for supplementary use of amino acids is to provide scientific evidence and scientific logic for the establishment of tolerable upper intake levels (UL) for amino acids. At present, however, execution of risk assessment for amino acids is hampered by deficiencies in necessary scientific information, particularly, experimental or clinical/epidemiological data related to the estimation of no-observed-adverse-effect-levels (NOAEL), and scientific principles for the allocation of uncertainty factors (UF) in extrapolation from experimental/clinical data to the general human population. This paper attempts to identify the scientific data and scientific thoughts/methodologies required for deriving UL or assessing the margin of safety for the supplementary use of amino acids.

KEY WORDS: • amino acids • dietary reference intake (DRI) • tolerable upper intake level (UL) • metabolomics

This article has been cited by other articles:

				D. Paddon-Jones, K. R Short, W. W Campbell, E. Volpi, and R. R Wolfe Role of dietary protein in the sarcopenia of aging Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1562S - 1566S. [Abstract] [Full Text] [PDF]

				W. M. Rand Variability in Planning and Assessment: Statistical Considerations and Models J. Nutr., June 1, 2004; 134(6): 1610S - 1616S. [Abstract] [Full Text] [PDF]

				A. Martin, M. Touvier, and J.-L. Volatier The Basis for Setting the Upper Range of Adequate Intake for Regulation of Macronutrient Intakes, Especially Amino Acids J. Nutr., June 1, 2004; 134(6): 1625S - 1629S. [Abstract] [Full Text] [PDF]

				P. Maruvada and S. Srivastava Biomarkers for Cancer Diagnosis: Implications for Nutritional Research J. Nutr., June 1, 2004; 134(6): 1640S - 1645S. [Abstract] [Full Text] [PDF]

				R. Sakai, M. Miura, M. Amao, R. Kodama, S. Toue, Y. Noguchi, and T. Kimura Potential Approaches to the Assessment of Amino Acid Adequacy in Rats: A Progress Report J. Nutr., June 1, 2004; 134(6): 1651S - 1655S. [Abstract] [Full Text] [PDF]